Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

calcium ion transport

4

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

3

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1965

3

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Metabolic acidosis

3

Heart diseases

1

Nutritional requirements

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

Diagnostic

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bellon, France

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

EPA CompTox

4

FDA UNII

4

PUBCHEM

4

ECHA (EC/EINECS)

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

BLOOD AND BLOOD FORMING ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

I.V. SOLUTION ADDITIVES

1

I.V. SOLUTIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other i.v. solution additives

1

Solutions affecting the electrolyte balance

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TROMETHAMINE

023C2WHX2V

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1965

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

calcium ion transport

Conditions:

Metabolic acidosis

Tromethamine is extensively used in biochemistry and molecular biology. Because tromethamine (in the form of R-NH2) is a proton acceptor with a pK of 7.8, it is an effective buffer that can be used to maintain the pH of body fluids. Tromethamine is i...

ndicated for the prevention and correction of metabolic acidosis. When administered intravenously as a 0.3 M solution, tromethamine acts as a proton acceptor and prevents or corrects acidosis by actively binding hydrogen ions (H+). It binds not only cations of fixed or metabolic acids, but also hydrogen ions of carbonic acid, thus increasing bicarbonate anion (HCO3‾). TromeThamine also acts as an osmotic diuretic, increasing urine flow, urinary pH, and excretion of fixed acids, carbon dioxide and electrolytes. A significant fraction of tromethamine (30% at pH 7.40) is not ionized and therefore is capable of reaching equilibrium in total body water. This portion may penetrate cells and may neutralize acidic ions of the intracellular fluid.

MANGANESE GLYCINATE

B49L2D4K1D

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

calcium ion transport

Conditions:

Nutritional requirements

MANGANESE GLYCINATE is composed of trace mineral manganese and an amino acid, glycine. It is easily absorbable. It helps the body in a variety of ways including formation of clotting factors, connective tissue sex hormones and bones. It helps in the ...

absorption of calcium and metabolism of carbohydrate as well as fat. It plays an important role for normal nerve and brain function. Moreover, it is a component of the enzyme, superoxide dismutase which helps fighting free radicals. Decreased manganese level can cause infertility, seizures, weakness and bone malformation. Manganese Glycinate (Mn(glycinate)2) has application as a contrast enhancement agent for magnetic resonance imaging in the heart. Toxicity, which is primarily due to the action of manganese as a calcium channel blocker with effects on muscle electrophysiology and contractility, has limited the use of manganese salts as paramagnetic contrast agents. Mn(glycinate)2 exerts its negative inotropic effect, at least partially, by interfering with the function of the L-type Ca channels at high concentrations.

TROMETHAMINE HYDROCHLORIDE

383V75M34E

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1965

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

calcium ion transport

Conditions:

Metabolic acidosis

Tromethamine is extensively used in biochemistry and molecular biology. Because tromethamine (in the form of R-NH2) is a proton acceptor with a pK of 7.8, it is an effective buffer that can be used to maintain the pH of body fluids. Tromethamine is i...

ndicated for the prevention and correction of metabolic acidosis. When administered intravenously as a 0.3 M solution, tromethamine acts as a proton acceptor and prevents or corrects acidosis by actively binding hydrogen ions (H+). It binds not only cations of fixed or metabolic acids, but also hydrogen ions of carbonic acid, thus increasing bicarbonate anion (HCO3‾). TromeThamine also acts as an osmotic diuretic, increasing urine flow, urinary pH, and excretion of fixed acids, carbon dioxide and electrolytes. A significant fraction of tromethamine (30% at pH 7.40) is not ionized and therefore is capable of reaching equilibrium in total body water. This portion may penetrate cells and may neutralize acidic ions of the intracellular fluid.

TROMETAMOL ACETATE

YYB8UMN69X

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 1965

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

calcium ion transport

Conditions:

Metabolic acidosis

Tromethamine is extensively used in biochemistry and molecular biology. Because tromethamine (in the form of R-NH2) is a proton acceptor with a pK of 7.8, it is an effective buffer that can be used to maintain the pH of body fluids. Tromethamine is i...

ndicated for the prevention and correction of metabolic acidosis. When administered intravenously as a 0.3 M solution, tromethamine acts as a proton acceptor and prevents or corrects acidosis by actively binding hydrogen ions (H+). It binds not only cations of fixed or metabolic acids, but also hydrogen ions of carbonic acid, thus increasing bicarbonate anion (HCO3‾). TromeThamine also acts as an osmotic diuretic, increasing urine flow, urinary pH, and excretion of fixed acids, carbon dioxide and electrolytes. A significant fraction of tromethamine (30% at pH 7.40) is not ionized and therefore is capable of reaching equilibrium in total body water. This portion may penetrate cells and may neutralize acidic ions of the intracellular fluid.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1